NCT04028960终止2 期
Intranasal Insulin: A Novel Therapy for Hypoglycemia Unawareness in Type 1 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Percentage of Time With Dangerous Hypoglycemia
研究概览
简要总结
The purpose of this study is to determine how Humulin-R regular insulin affects the body's ability to feel low blood sugar (hypoglycemia) when delivered intranasally compared to placebo in subjects with Type 1 Diabetes (T1D) with hypoglycemia awareness. The study will use continuous glucose monitoring (CGM) to collect this information. The study drug or placebo will be administered using an intranasal device.
详细描述
Hypoglycemia occurs with high frequency among patients with T1D. With repeated episodes of hypoglycemia, the counter-regulatory pathways to restore normal glucose are blunted, and patients can become unaware of the hypoglycemia. It is estimated that 40% of patients with T1D have hypoglycemia unawareness.
The study has the following objectives:
- Primary:
a. To assess non-inferiority of dangerous hypoglycemia with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia. 2. Secondary:
- To describe changes in overall glycemic control with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia
- To describe changes in hypoglycemia awareness with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia
- To describe changes in safety endpoints with administration of intranasal insulin in T1D participants with intact awareness of hypoglycemia.
- Exploratory:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult patients (age ≥18) with type 1 diabetes diagnosis and a duration of diabetes of at least 10 years
- •Gold score <4
- •HbA1c ≥6.5% within the last 3 months or at screen visit
- •Stable insulin regimen (MDI or insulin pump) for at least 3 months, as deemed stable by principal investigator
- •Depression/anxiety medications stable for at least 3 months
- •Ability and willingness to wear CGM continuously during study participation
- •Participants must use their own smartphone, and have the ability and willingness to use CGM smartphone applications compatible with their smartphone
- •Ability and willingness to check self-monitoring of blood glucose (SMBG) using own supplies, as instructed by study staff
- •Ability and willingness to document when having symptoms of hypoglycemia in the CGM smartphone app or in a diary
- •Willing to operate insulin pump without threshold suspend feature or hybrid closed-loop, if applicable
- •Proficient in speaking, reading and understanding English in order to complete surveys and testing of cognitive function
- •Women of child-bearing age must agree to procure and use contraception throughout the study
排除标准
- •Pregnancy or planning pregnancy
- •eGFR ≤ 30 mL/min per 1.73 m2, if available from medical record
- •Completed any other research study within 6 months of screening date
- •Current or recent use within 3 months of an insulin delivery system that adjusts insulin in response to continuous glucose monitoring (CGM) data (such as an automated insulin delivery system like hybrid closed-loop insulin pump therapy)
- •Known dementia or mild cognitive impairment diagnosis
- •Diabetic ketoacidosis within the last 6 months
- •Use of non-insulin medications to treat diabetes
- •Those planning to change diet or exercise regimen during the study
- •History of trans-sphenoidal surgery or surgery to the upper part of the nasal cavity, chronic sinusitis, severe deviated septum, or difficulty with smell and/or taste
- •Severe psychiatric illness
- •Allergy to adhesives, insulin or any components of insulin product
- •Subject cannot adequately demonstrate ability to use and deploy the devices as determined by investigator
- •Evidence of suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS)
- •Subject has history of any of the following: moderate to severe pulmonary disease, poorly controlled congestive heart failure, significant cardiovascular and/or cerebrovascular events within previous 6 months, condition known to affect absorption, distribution, metabolism, or excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other clinically relevant abnormality or illness that inclusion would pose a safety risk to the subject as determined by investigator.
研究组 & 干预措施
Placebo
Placebo Comparator
No active drug
干预措施: SipNose intranasal device (Device)
Humulin-R
Experimental
Insulin
干预措施: Regular insulin (Humulin-R), intranasal route (Drug)
Humulin-R
Experimental
Insulin
干预措施: SipNose intranasal device (Device)
结局指标
主要结局
Percentage of Time With Dangerous Hypoglycemia
时间窗: Two 14-20 day treatment periods
Defined using percent time below range (\<54 mg/dL), from real-time continuous glucose monitoring (CGM)
次要结局
- Percent of Time With Blood Glucose 70-180 mg/dL(Two 14-20 day treatment periods)
- Percentage of Time With Blood Glucose <70 mg/dL(Two 14-20 day treatment periods)
- Percentage of Time Blood Glucose >180 mg/dL(Two 14-20 day treatment periods)
- Percentage of Time With Blood Glucose >250 mg/dL(Two 14-20 day treatment periods)
- Percentage of Time Participant Had Active Sensor Wear(Two 14-20 day treatment periods)
- Mean Glucose From the Study Participants(Two 14-20 day treatment periods)
- Coefficient of Variation (%CV) of Blood Glucose Values From CGM Data(Two 14-20 day treatment periods)
- Glucose Management Indicator (GMI)(Two 14-20 day treatment periods)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)Mild Cognitive ImpairmentAlzheimer's DiseaseNCT00438568University of Washington173
已完成
1 期
Intranasal Insulin for Improving Cognitive Function in Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary ProgressiveNCT02988401Johns Hopkins University105
招募中
2 期
Evaluating the effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trialIRCT20191022045196N1Shahid Beheshti University of Medical Sciences40
已完成
不适用
Effect of intranasal insulin administering on patients with loss of smellIRCT2017061712782N15Vice chancellor for research,Isfahan University of Medical Sciences36
已完成
3 期
The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar DisorderBipolar DisorderNCT00314314University Health Network, Toronto60